# Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

> **NCT05174169** · PHASE2,PHASE3 · RECRUITING · sponsor: **NRG Oncology** · enrollment: 1912 (estimated)

## Conditions studied

- Stage III Colon Cancer

## Interventions

- **DEVICE:** Signatera test
- **DRUG:** mFOLFOX6 3-6 month
- **DRUG:** CAPOX 3 month
- **DRUG:** mFOLFIRINOX
- **DRUG:** mFOLFOX6 6 month
- **DRUG:** CAPOX 6 month

## Key facts

- **NCT ID:** NCT05174169
- **Lead sponsor:** NRG Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-08
- **Primary completion:** 2029-03-10
- **Final completion:** 2030-03-10
- **Target enrollment:** 1912 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05174169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05174169, "Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05174169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*